$AMRS Today was an exciting day for Amyris the Healthcare Company. It has been clear that neither Amyris nor IDRI is in a position to drive this vaccine platform to clinical trials on their own, and so a partnership was inevitable. Whether this vaccine eventually becomes approved or not, the bottom line is that someone (Nant Africa in this case) evaluated their pre-clinical data and decided to pay them money for its rights. Lots more will emerge about this partnership and possible future opportunities, but for me, this last point is what matters most. This is external validation that Amyris has indeed identified pharmaceutical grade squalene and a functional vaccine platform. Lots is going on in the vaccine space for Amyris. Below, I thought it would be helpful to summarize some key concepts for interpretation of future updates: